So Much for New Ideas

The Wall Street Journal's Health Blog reports that Pfizer named Martin Mackay as the new chief of their struggling R&D program. Jacob Goldstein adds that Mackay, who has been at Pfizer for over ten years, is an odd choice since Pfizer had been looking to bring in fresh blood. Pfizer also announced the launch of a dedicated biotech unit in San Franciso that will be run by Corey Goodman.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

In an editorial, officials from scientific societies in the US and China call for the international community to develop criteria and standards for human germline editing.

The Washington Post reports on a Federal Bureau of Investigation plan to place rapid DNA analyzers at booking stations around the country.

The US National Institutes of Health is to review studies that have received private support for conflicts of interest, according to the New York Times.

In Science this week: the PsychENCODE Consortium reports on the molecular mechanisms of neuropsychiatric disorders, and more.